Han Jung

Corporate Officer/Principal presso Korean Institute of Certified Public Accountants

Health Technology

Profilo

Han Jung is currently a Member at the Korean Institute of Certified Public Accountants.
Previously, Mr. Jung worked as a Director at Glycostem Therapeutics BV.

Posizioni attive di Han Jung

Società	Posizione	Inizio
Korean Institute of Certified Public Accountants	Corporate Officer/Principal	-

Tutte le posizioni attive di Han Jung

Precedenti posizioni note di Han Jung

Società	Posizione	Fine
Glycostem Therapeutics BV Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Han Jung

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Han Jung

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Korean Institute of Certified Public Accountants
Glycostem Therapeutics BV Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands.	Health Technology